Bcl-2 as Prognostic Factor in Head and Neck Squamous Cell Carcinoma
Abstract:A series of 66 cases of oral squamous cell carcinoma (OSCC) was retrospectively analyzed by immunohistochemistry for bcl-2 expression to verify its predictive value for clinical outcome in patients with OSCC. After grouping for bcl-2 expression, OSCCs were statistically analyzed for the variables age, gender, histological grading (G), TNM, staging, recurrence, and overall survival rate. Univariate and multivariate (Cox regression) analyses were performed. Thirty-six OSCC (54.5%) showed expression for bcl-2, whereas 30 (44.5%) were negative. No statistical association was found between bcl-2 expression and any variables considered at baseline. Overall disease-specific survival rate at 72 months was 51%, independently from the extent of the tumor. In terms of prognostic significance, the bcl-2-positive group showed more than 60% survival at 72 months whereas the bcl-2-negative group showed none. An independent association of bcl-2 expression was found with an improved overall survival rate (p = 0.048), although grading and staging were established to be the best baseline markers of prognosis. On the basis of these results, it is possible to suggest bcl-2 as an early marker of prognosis: lack of bcl-2 expression could constitute a hallmark of aggressive biological behavior in OSCC.
Document Type: Research Article
Affiliations: 1: Department of Surgical Sciences, University of Foggia, Foggia, Italy 2: Institute of Histology, University of Bologna, Bologna, Italy 3: Institute of Pathology, University of Ancona, Ancona, Italy 4: Department of Dental Sciences, University of Palermo, Palermo, Italy 5: Department of Biomorphological and Functional Sciences-Pathology Unit, University of Naples Federico II, Naples, Italy 6: Department of Surgical Sciences, University of L'Aquila, L'Aquila, Italy 7: Institute of Maxillofacial Surgery, University of Ferrara, Ferrara, Italy
Publication date: May 1, 2005
- Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.